Leesa Gentry - 01 Mar 2024 Form 3 Insider Report for RenovoRx, Inc. (RNXT)

Role
Chief Clinical Officer
Signature
/s/ Leesa Gentry
Issuer symbol
RNXT
Transactions as of
01 Mar 2024
Net transactions value
$0
Form type
3
Filing time
08 Mar 2024, 16:26:04 UTC
Next filing
08 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RNXT Options 01 Mar 2024 Common Stock 62,500 $2.11 Direct F1
holding RNXT Options 01 Mar 2024 Common Stock 19,413 $1.08 Direct F2
holding RNXT Options 01 Mar 2024 Common Stock 60,159 $1.08 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 10-year incentive stock options granted to the reporting person on June 1, 2023 pursuant to Company's 2021 Omnibus Equity Incentive Plan (the "Plan"). One-fourth of the shares subject to the option vest on April 10, 2024 and 1/36th of the remaining shares vest monthly thereafter.
F2 Represents 10-year stock non-qualified stock options granted to the reporting person on January 19, 2024 pursuant to the Plan as a bonus. These options were fully vested upon issuance.
F3 Represents 10-year stock incentive stock options granted to the reporting person on January 19, 2024 pursuant to the Plan. These options vest at a rate of 1/48 per month beginning on February 1, 2024.